Showing 381-400 of 503 for: Cochrane Systematic Reviews > Neurologic 
- Psychological and behavioural treatments for adults with non-epileptic attack disorder
Cochrane Systematic Reviews, 11-Feb-2014
Psychogenic non-epileptic seizures, also known as non-epileptic attack disorder (NEAD), have the outward appearance of epilepsy in the absence of physiological or electroencephalographic correlates. Non-epileptic seizures can occur in isolation or in comb
- Psychological interventions for multiple sclerosis
Cochrane Systematic Reviews, 17-Sep-2008
The unpredictable, variable nature of Multiple Sclerosis (MS), and the possibility of increasing disability, means that a diagnosis can have substantial psychological consequences.
- Psychological therapies for the management of chronic and recurrent pain in children and adolescents
Cochrane Systematic Reviews, 9-Feb-2016
This is an update of the original Cochrane review first published in Issue 1, 2003, and previously updated in 2009 and 2012. Chronic pain affects many children, who report severe pain, disability, and distressed mood. Psychological therapies are emerging
- Psychological therapies for the management of chronic pain (excluding headache) in adults
Cochrane Systematic Reviews, 23-Feb-2016
Psychological treatments are designed to treat pain, distress and disability, and are in common practice. This review updates and extends the 2009 version of this systematic review.
- Psychological treatment for anxiety in people with traumatic brain injury
Cochrane Systematic Reviews, 14-Mar-2012
Psychological treatments are commonly used in the management of anxiety. Certain types of psychological treatments are well suited to needs of people with traumatic brain injury (TBI). We have systematically reviewed studies examining the effectiveness of
- Psychological treatments for epilepsy
Cochrane Systematic Reviews, 24-Feb-2016
Psychological interventions such as relaxation therapy, cognitive behaviour therapy, bio-feedback and educational interventions have been used alone or in combination in the treatment of epilepsy, to reduce the seizure frequency and improve the quality of
- Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy
Cochrane Systematic Reviews, 18-Jan-2011
Excessive daytime sleepiness is a common symptom of myotonic dystrophy. Psychostimulants are drugs increasingly used to treat hypersomnia in myotonic dystrophy.
- Rapid versus slow withdrawal of antiepileptic drugs
Cochrane Systematic Reviews, 10-Jan-2022
The ideal objective of treating a person with epilepsy is to induce remission (free of seizures for some time) using antiepileptic drugs (AEDs) and withdraw the AEDs without causing seizure recurrence. Prolonged usage of AEDs may have long-term adverse ef
- Reality orientation for dementia
Cochrane Systematic Reviews, 6-Nov-2008
Reality Orientation (RO) was first described as a technique to improve the quality of life of confused elderly people, although its origins lie in an attempt to rehabilitate severely disturbed war veterans, not in geriatric work. It operates through the p
- Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease
Cochrane Systematic Reviews, 16-Oct-2012
Recombinant human insulin-like growth factor I (rhIGF-I) is a possible disease modifying therapy for amyotrophic lateral sclerosis (ALS, which is also known as motor neuron disease (MND)).
- Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis
Cochrane Systematic Reviews, 27-Oct-2008
Immunomodulatory drugs have been shown to be only modestly effective in clinically definite relapsing remitting multiple sclerosis (RRMS). It has been hypothesized that their efficacy could be higher if used at the first appearance of symptoms, that is in
- Rehabilitation interventions for foot drop in neuromuscular disease
Cochrane Systematic Reviews, 17-Feb-2015
"Foot drop" or "Floppy foot drop" is the term commonly used to describe weakness or contracture of the muscles around the ankle joint. It may arise from many neuromuscular diseases.
- Remacemide for drug-resistant localization related epilepsy
Cochrane Systematic Reviews, 1-May-2012
This is an updated version of the original Cochrane review published in issue 4, 2002.
- Reminiscence therapy for dementia
Cochrane Systematic Reviews, 6-Nov-2008
Reminiscence Therapy (RT) involves the discussion of past activities, events and experiences with another person or group of people, usually with the aid of tangible prompts such as photographs, household and other familiar items from the past, music and
- Repetitive transcranial magnetic stimulation for the treatment of amyotrophic lateral sclerosis or motor neuron disease
Cochrane Systematic Reviews, 23-Apr-2013
Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is a progressive neurodegenerative disease without effective therapies. Several studies have suggested that repetitive transcranial magnetic stimulation (rTMS) may have positiv
- Respite care for people with dementia and their carers
Cochrane Systematic Reviews, 16-Jan-2014
Caring for someone with dementia can be emotionally and physically demanding. Respite care is any intervention designed to give rest or relief to caregivers. It is not clear what positive and negative effects such care may have on them, or on people with
- Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
Cochrane Systematic Reviews, 14-Feb-2012
Riluzole is approved for the treatment of amyotrophic lateral sclerosis in most countries. Questions persist about its clinical utility because of high cost and modest efficacy.
- Risperidone alone or in combination for acute mania
Cochrane Systematic Reviews, 4-Nov-2008
Risperidone, an atypical antipsychotic, is used to treat mania both alone and in combination with other medicines.
- Risperidone for attention-deficit hyperactivity disorder in people with intellectual disabilities
Cochrane Systematic Reviews, 13-Apr-2010
Attention deficit hyperactivity disorder (ADHD) is increasingly recognised as occurring in people with intellectual disability (ID), although treatment of ADHD in this population has not ben tested widely. Risperidone has been used to treat ADHD in people
- Risperidone for autism spectrum disorder
Cochrane Systematic Reviews, 21-Oct-2009
Autistic spectrum disorder encompasses a wide variety of behavioural and communicative problems. Both the core features and non-core features of autism have been targeted in a variety of therapies. Atypical antipsychotic medications, including risperidone
